Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

20 septembre 2019 mis à jour par: GlaxoSmithKline
The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

The purpose of this study is to demonstrate the efficacy and safety of belimumab 10mg/kg administered intravenously (IV) every 4 weeks compared to placebo, in patients with SLE when added to standard of care therapy, as measured by the SLE Responder Index (SRI) at 52 weeks, defined by a composite endpoint using SELENA SLEDAI score, Physician's Global Assessment (PGA) and BILAG A and B organ domain scores.

Type d'étude

Interventionnel

Inscription (Réel)

709

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Chine
      • Beijing, Chine, 100044
        • GSK Investigational Site
      • Beijing, Chine, 100029
        • GSK Investigational Site
      • Beijing, Chine, 100032
        • GSK Investigational Site
      • Chongqing, Chine, 400038
        • GSK Investigational Site
      • Shanghai, Chine, 200025
        • GSK Investigational Site
      • Shanghai, Chine, 200433
        • GSK Investigational Site
      • Shanghai, Chine, 200001
        • GSK Investigational Site
      • Shanghai, Chine, 200003
        • GSK Investigational Site
      • Tianjin, Chine, 300052
        • GSK Investigational Site
    • Anhui
      • Hefei, Anhui, Chine, 230001
        • GSK Investigational Site
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510080
        • GSK Investigational Site
      • Guangzhou, Guangdong, Chine, 510630
        • GSK Investigational Site
      • Guangzhou, Guangdong, Chine, 510260
        • GSK Investigational Site
    • Heilongjiang
      • Harbin, Heilongjiang, Chine, 150001
        • GSK Investigational Site
    • Hunan
      • Changsha, Hunan, Chine, 410011
        • GSK Investigational Site
      • Changsha, Hunan, Chine, 410008
        • GSK Investigational Site
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210029
        • GSK Investigational Site
      • Suzhou, Jiangsu, Chine, 215006
        • GSK Investigational Site
    • Shaanxi
      • Xian, Shaanxi, Chine, 710032
        • GSK Investigational Site
    • Shandong
      • Jinan, Shandong, Chine, 250012
        • GSK Investigational Site
    • Sichuan
      • Chengdu, Sichuan, Chine, 610041
        • GSK Investigational Site
    • Yunnan
      • Kunming, Yunnan, Chine, 650101
        • GSK Investigational Site
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310009
        • GSK Investigational Site
  • Corée, République de
      • Busan, Corée, République de
        • GSK Investigational Site
      • Daegu, Corée, République de, 700-721
        • GSK Investigational Site
      • Incheon, Corée, République de, 400-711
        • GSK Investigational Site
      • Seoul, Corée, République de, 137-701
        • GSK Investigational Site
      • Seoul, Corée, République de, 110-744
        • GSK Investigational Site
      • Seoul, Corée, République de
        • GSK Investigational Site
      • Seoul, Corée, République de, 133-792
        • GSK Investigational Site
      • Suwon, Kyonggi-do, Corée, République de, 443-721
        • GSK Investigational Site
  • Japon
      • Chiba, Japon, 275-8580
        • GSK Investigational Site
      • Ehime, Japon, 791-0295
        • GSK Investigational Site
      • Fukuoka, Japon, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japon, 810-8563
        • GSK Investigational Site
      • Hiroshima, Japon, 730-8619
        • GSK Investigational Site
      • Hiroshima, Japon, 739-0002
        • GSK Investigational Site
      • Hokkaido, Japon, 060-8648
        • GSK Investigational Site
      • Hokkaido, Japon, 060-8604
        • GSK Investigational Site
      • Hyogo, Japon, 675-8545
        • GSK Investigational Site
      • Miyagi, Japon, 980-8574
        • GSK Investigational Site
      • Nagasaki, Japon, 852-8501
        • GSK Investigational Site
      • Nagasaki, Japon, 857-1195
        • GSK Investigational Site
      • Okayama, Japon, 710-0824
        • GSK Investigational Site
      • Okinawa, Japon, 901-0243
        • GSK Investigational Site
      • Tochigi, Japon, 321-0293
        • GSK Investigational Site
      • Tokyo, Japon, 113-8431
        • GSK Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age 18 years and older.
  • Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria.
  • Have active SLE disease.
  • Have positive anti-nuclear antibody (ANA) test results.
  • Are on a stable SLE treatment regimen.
  • Females of childbearing age are willing to use appropriate contraception

Exclusion Criteria:

  • Have received treatment with any B cell targeted therapy at any time.
  • Have received a biologic investigational agent in the past year.
  • Have received 3 or more courses of systemic corticosteroids in the past year.
  • Have received intravenous (IV) cyclophosphamide within 180 days prior to Day 0.
  • Have severe lupus kidney disease.
  • Have active central nervous system (CNS) lupus.
  • Have had a major organ transplant.
  • Have significant unstable or uncontrolled acute or chronic diseases or conditions not due to SLE.
  • Have a planned surgical procedure.
  • Cancer within the last 5 years, except for adequately treated skin cancer, or carcinoma in situ of the uterine cervix.
  • Have required management of acute or chronic infections in the past 60 days.
  • Have current drug or alcohol abuse or dependence.
  • Have a historically positive test, or test positive at screening for HIV, Hepatitis B, or Hepatitis C.
  • Have an IgA deficiency.
  • Have severe laboratory Abnormalities.
  • Have had anaphylactic reaction to X-ray contrast agents or biologic agents.
  • Suicidal behavior or ideation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo
placebo
Médicament: Placebo
Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Expérimental: Belimumab
10mg/kg
Médicament: Belimumab
10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.
Délai: Week 52
SRI response is a composite index, defined as the percent of participants with >=4 point reduction from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score and no worsening (increase of < 0.30 points from Baseline) in physicians global assessment (PGA) and no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).
Week 52

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percent of Participants With >=4 Point Reduction From Baseline in SELENA SLEDAI Score at Week 52 for Double-blind Phase.
Délai: Baseline (Day 0) and Week 52
The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. The Baseline value of a variable is defined as the value of the variable measured at Day 0 prior to dosing. In case of multiple results on Day 0 prior to dosing, the latest result was used. If a Day 0 value was not available, the last available value prior to Day 0 was used.
Baseline (Day 0) and Week 52
Percent of Participants With SRI7 Response at Week 52 for Double-blind Phase.
Délai: Baseline (Day 0) and Week 52
SRI7 response is defined as the percent of participants with >=7 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).
Baseline (Day 0) and Week 52
Number of Days of Daily Prednisone Dose <=7.5 mg/Day and/or Reduced by 50 Percent From Baseline Over 52 Weeks for Double-blind Phase.
Délai: Week 52
Number of days of daily prednisone dose <=7.5 mg/day and/or reduced by 50 percent over time through each scheduled visit during the blinded period were compared between belimumab and placebo using Rank ANCOVA model which was used for comparing belimumab and placebo. The independent variables in the model included treatment group, Baseline prednisone dose level, country, Baseline SELENA SLEDAI score (<=9 vs. >=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). This analysis was perfomed on the participants who used prednisone >7.5 mg/day at Baseline.
Week 52
Time to First Severe SLE Flare Index (SFI) Flare Over 52 Weeks for Double-blind Phase.
Délai: 52 weeks
Time to first severe SLE flare is defined as the number of days from first treatment until the participant had an event (event date-treatement start date +1). If a participant had a severe SFI flare and received protocol restricted medication then the event date was the earliest of the first severe SFI flare date, and the treatment failure date. Analysis of severe SFI flare was performed on the modified SELENA SLEDAI SLE flare index in which the modification excluded severe flares that were triggered only by an increase in SELENA SLEDAI score to >12. Analysis was from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for country, Baseline SELENA SLEDAI score (<=9 vs. >=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4).
52 weeks
Percent of Participants Achieving SLE SRI Response Rate for Open-label (OL) Phase
Délai: Weeks 24 and 48 for Years 2, 3, 4, 5 and 6
SRI response is a composite index, defined as the percent of participants with >=4 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at time of assessment. Excludes participants with a SELENA SLEDAI score <4 at baseline. Participants randomized to belimumab in double-blinded (DB) phase, Baseline is last available value before first belimumab dose received in DB phase. Participants randomized to placebo in DB phase, Baseline is last available value before receiving first belimumab dose in OL phase. Observed case data are presented.Year 6 Week 48 is the Exit Visit obtained by slotting the Exit Visit to Week 48. A SELENA SLEDAI score of 0 (no lupus activity) and a score of 105 (maximum). PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range.
Weeks 24 and 48 for Years 2, 3, 4, 5 and 6

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

GlaxoSmithKline

Collaborateurs

Human Genome Sciences Inc.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

23 mai 2011

Achèvement primaire (Réel)

15 septembre 2015

Achèvement de l'étude (Réel)

21 septembre 2018

Dates d'inscription aux études

Première soumission

28 avril 2011

Première soumission répondant aux critères de contrôle qualité

28 avril 2011

Première publication (Estimation)

2 mai 2011

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 octobre 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 septembre 2019

Dernière vérification

1 septembre 2019

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 113750

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Le lupus érythémateux disséminé

Essais cliniques sur Belimumab

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Canada

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner